|
Post by patten1962 on Sept 24, 2018 20:28:17 GMT -5
I want to say how helpful this board is! I am excited to be a Mannkind Long. Honestly very excited to see what the SP does the next few Days/Weeks! Only news coming is all good!
😁
|
|
|
Post by sayhey24 on Sept 24, 2018 20:51:49 GMT -5
For me the big news today was Mike saying Bluehale is being integrated with Apple Health. We have been talking about cloud monitoring and a big tech partner here for a long time. It seems some progress is being made. 1:53:00 mark media.rampard.com/UTHR_SD2018/index.jsp
|
|
|
Post by mango on Sept 25, 2018 8:00:58 GMT -5
Just watched Mike’s presentation. It is without question, his best one yet. Grateful for Mike and happy he made a true friendship with UT.
Based on the Phase 1 Tret data that Mike revealed, it is obvious that TreT is a revolutionary medical advancement in the treatment of PAH. This will positively impact so many and will be unbelievably life-changing for people with this debilitating condition.
How can anyone not be excited for people with PAH?
|
|
|
Post by mnholdem on Sept 25, 2018 8:41:55 GMT -5
To add to the above comments, the pump works continuously for 48 hrs and is then replaced. They didn't mention if they were recycled by the factory or you just throw it out. Sounds expensive/wasteful. The drug volume is pretty small. My guess is 10cc/day. Apparently all batteries expand when they are being discharged and the pump uses the swelling of the battery to force the drug out of a small bladder. Seems like a novel and clever way to accurately dispense small volumes. I think the reason the other treatments use an IV or a pump because the drug needs to be continuously put into the patient. I might be wrong about this. The big unknown to me is how TrepT can deliver a constant and continuous supply of the drug. The trial used healthy patients so this wouldn't really be an issue for the trial. I don't think Mike mentioned anything about this. I'm sure there is a good answer, I just don't know what it is. Treprostinil isn’t delivered continuously. Patients take multiple inhalations several times a day.
|
|
|
Post by mango on Sept 25, 2018 9:01:10 GMT -5
Current therapeutic effects of inhaled Treprostinil lasts ~ 4 hours.
Considering that what Mike disclosed is essentially that people will be able to easily take the current daily target dose of 216mcg in a single inhalation. We are aiming way beyond the 216mcg. The Phase 1 participants were healthy volunteers and they reached just 36mcg shy of the daily target dose with Tyvaso, which requires 4 individual treatment sessions spaced hours apart, involving 9 inhalations per treatment sessions (~54mcg), and the sessions are spaced hours apart, essentially over a 12 hour time span.
With TreT, you achieve all that and then some in literally a single inhalation, at the location of your choice, and 2-3 seconds of your time. 😎
|
|
|
Post by Omega on Sept 25, 2018 12:01:29 GMT -5
|
|
|
Post by ilovekauai on Sept 25, 2018 12:58:44 GMT -5
Mahalo for posting these Omega! I see Dr. Kendall's handprint all over these too.
|
|
|
Post by sportsrancho on Sept 25, 2018 14:06:17 GMT -5
|
|
|
Post by kc on Sept 25, 2018 14:38:24 GMT -5
Mike starts at the 1:48 mark. Good presentation.
|
|
|
Post by kc on Sept 25, 2018 14:40:39 GMT -5
Can someone give a detailed report? Did Mike or anyone else allude to the other UT/MannKind Technosphere applications? I’ve noticed vaccines mentioned couple times now in the slides. Many of today’s vaccines are totally unsafe. Maybe the TechnoVax partnership will resurface someday in the future. Mike did mention epinephrine so I would think that they are also working behind the scene with that product. I bet that would interest United also giving them another drug to sell.
|
|
|
Post by kc on Sept 25, 2018 14:48:59 GMT -5
Thanks Jeff, you called it!! And thanks for reminding us all to pay attention! You get the credit. You are awesome! Like the JP Morgan question and the answer of that question. Development paths is fast track bio equivalence study... unbelievable delivery system. easier to use delivery system
|
|
|
Post by uvula on Sept 25, 2018 14:53:15 GMT -5
I get the feeling that if UH talked to mnkd before talking to Steadymed, there would never have been a UH development program with Steadymed.
|
|
|
Post by kc on Sept 25, 2018 14:57:09 GMT -5
Current therapeutic effects of inhaled Treprostinil lasts ~ 4 hours. Considering that what Mike disclosed is essentially that people will be able to easily take the current daily target dose of 216mcg in a single inhalation. We are aiming way beyond the 216mcg. The Phase 1 participants were healthy volunteers and they reached just 36mcg shy of the daily target dose with Tyvaso, which requires 4 individual treatment sessions spaced hours apart, involving 9 inhalations per treatment sessions (~54mcg), and the sessions are spaced hours apart, essentially over a 12 hour time span. With TreT, you achieve all that and then some in literally a single inhalation, at the location of your choice, and 2-3 seconds of your time. 😎 Current therapeutic effects of inhaled Treprostinil lasts ~ 4 hours. Can you imaging how much easier life will be for a person with PAH being able to carry their Technosphere device vs the current Tyvaso bong. Daily life is going to be much easier for the PAH patient.
I think we have a winner here and this will lead into other inhalable drugs. Not a drug expert but I think the game is finding something that they can be equal to a already approved drug. MannKind made the right choice in picking Treprostinil. They must have really done their home work on it vs epinephrine or they would have gone in that direction first. Somehow MannKind knew or exploited a weak spot known publically that United was struggling with on their device.
Next I hope its epinephrine as it could make the game on for MannKind shareholders. The future is looking brighter everyday.
|
|
|
Post by lsl428 on Sept 25, 2018 15:03:14 GMT -5
I agree that was a pretty solid presentation....Optics are everything as most are aware...I think Mike does a pretty good job of being the Face of Mannkind .. Delivery and body language could be improved a bit but he stays on point and his demeanor is calm and likable. That was a great venue to get more light shed on the company at an opportune time.
|
|
|
Post by sportsrancho on Sept 25, 2018 15:18:42 GMT -5
I agree also, he comes off as very authentic, polite, confident, he’s got the answer to so many unmet needs right in his back pocket so to speak:-) He can step forward and very nicely and with class ...blow the competition away.
|
|